Keyphrases
Randomized Clinical Trial
50%
Obstructive Sleep Apnea
50%
Emergency Endotracheal Intubation
50%
Day Surgery
50%
Ambulatory Surgery
50%
Internalin B
50%
Preanesthetic Evaluation
50%
Evaluation Review
50%
Anesthesiologist
50%
Etomidate
50%
Opioid Reduction
50%
PAP Therapy
50%
Patients with Obesity
50%
Telemedicine
50%
Ketamine
50%
Adult Patients
50%
Postoperative Outcomes
25%
Anesthetic Techniques
25%
Surgery Patients
25%
Obesity
25%
Surgeons
25%
Denied Access
25%
Surgical Technique
25%
Ambulatory Outcome
25%
Independent Risk Factors
25%
Pre-anesthesia
22%
Preanesthesia
22%
Critically Ill Patients
18%
Healthcare Professionals
16%
Confidence Interval
12%
Emergency Intubation
12%
Clinical Trials
12%
Hemodynamically Unstable
6%
Anesthesiology
6%
Sedation
6%
Intubation
6%
No Significant Difference
6%
Survival Rate
6%
Induction Agents
6%
Medical Center
6%
Prospective Randomized Trial
6%
Single Center
6%
Survival Benefit
6%
Airway Team
6%
United States
6%
Specialist Services
5%
COVID-19 Pandemic
5%
Regulatory Barriers
5%
Anesthesia Practice
5%
Technology Training
5%
Medicine and Dentistry
Obstructive Sleep Apnea
100%
Anesthetic Agent
66%
Opiate
50%
Peroperative Complication
50%
General Anesthesia
50%
Regional Anesthesia
50%
Cardiorespiratory
50%
Cardiovascular Disease
50%
Etomidate
50%
Randomized Clinical Trial
50%
Postoperative Period
50%
Alertness
50%
Ketamine
50%
Patient with Obesity
50%
Disease Process
50%
Ambulatory Surgery
50%
Telemedicine
50%
Tracheal Intubation
50%
Anesthesiologist
33%
Arm
25%
Intubation
18%
Surgeon
16%
Surgical Technique
16%
Clinical Trial
12%
Anesthesiology
6%
Anesthesia Induction
6%
Quality Improvement
6%
Survival Rate
6%
Health Care Cost
5%
COVID-19
5%
Patient Satisfaction
5%
Pharmacology, Toxicology and Pharmaceutical Science
Ketamine
50%
Intubation
50%
Surface Plasmon Resonance
50%
Etomidate
50%
Randomized Clinical Trial
50%
Heparin
50%
Glycosaminoglycan
20%
Clinical Trial
12%
Listeria monocytogenes
10%
Oligosaccharide
10%
Protein Tyrosine Kinase
10%
Infectious Agent
10%
Binding Site
10%
Immunocompromised Patient
10%
Survival Rate
6%
